Jun 26, 2024 3:13pm EDT Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Jun 25, 2024 8:00am EDT Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024
Jun 20, 2024 8:00am EDT Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia
Jun 18, 2024 8:00am EDT Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS)
Jun 17, 2024 8:00am EDT Tonix Pharmaceuticals Presented Poster of Tonmya™ for the Management of Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2024
Jun 6, 2024 8:00am EDT Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024
